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模型，给予小鼠高脂饮食，腹腔注射 AICAR（AMPK 激活剂），发现 AICAR 可以显
著抑制小鼠肝癌的进展，他一方面减轻高脂造成的肝脏脂肪性病变，另一方面降
低了小鼠血清和刚脏中的白介素 6的水平，对白介素 6下游通路 STAT3有明显的
抑制作用。我们阐明了激活 AMPK可能抑制肝癌的进展，AMPK激活剂 AICAR可能
是未来肝癌治疗的潜在药物。 


















Hepatocellular carcinoma (HCC), the most common primary liver cancer, is 
closely linked to risk factors such as preexisting alcoholic liver disease, nonalcoholic 
steatohepatitis,and infection with hepatitis B and C viruses.These factors are all 
associated with inflammation, which plays a critical role intumorigenesis.In 
nonalcoholicsteatohepatitis, a condition in which fat accumulates intheliver, the 
common underlying factor is obesity, rather than alcohol abuse. Obesity has 
beenexamined as a potential risk factor for HCC.Indeed, epidemiological studies 
indicate that excess body weight and obesity may increase cancer risk. In men who 
were free of cancerat enrollment, individualswith high body mass index experience 
alarge, 4.5-fold increase in risk of death from liver cancerduring 16 years of 
follow-up.Obesitypromotes HCC development byenhancingproduction of the 
cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα), which cause 
hepatic inflammation, activate the oncogenic transcription factor STAT3 and 
triggertumorigenesis(Parket al., 2010),. Thus, there has long been a view that 
prevention ofobesity and associated metabolic diseases may also decrease the risk of 
liver cancer.  
In eukaryotic cells,AMP-activated protein kinase (AMPK) is a sensor of energy 
and nutrient status, and is a master regulator of metabolic homeostasis by switching 
off anabolic pathways, including synthesis of fatty acids, triglycerides, cholesterol, 
and proteins. Therefore, AMPK is a good pharmacological target to treat metabolic 
diseases such as obesity, type 2 diabetes and cardiovascular disease.At the same time, 
AMPK is also a potential cancer therapeutic, because itsactivation causes cell cycle 
arrest, presumably by suppressingmost of the metabolic changes that occur in rapidly 
proliferating cells.However, whether AMPK should be activated or inhibited during 
cancer therapy remains an open question, and requires further investigation. On the 
one hand, AMPK activation during energy stress has been shown to enhancesurvival 















glycolysis in cancer cells, and to suppress tumor growth in vivo. 
AICAR (5-aminoimidazole-4-carboxamideriboside) is a membrane-permeable 
prodrug that activates AMPK. In cells, AICAR is metabolizedto the nucleotide ZMP, 
an AMP analog with similar effects on the AMPK complex, including allosteric 
activation, T172 phosphorylation, and protection from dephosphorylation.Here, we 
chemically triggered HCC indiet-induced obese mice, and treated them with AICAR. 
We found that long-term AICAR treatment prevented hepatic steatosis, decreased IL-6 
production,and inhibited HCC development. Further, 
AICARsuppressedphosphorylation of the oncogenic transcription factor STAT3. 
These results suggestthat AMPK is a promising target to treat HCC,and that long-term 
AICAR administration prevents obesity-related liver cancer. 
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